INmune Bio Inc. (INMB)Healthcare | Biotechnology | Boca Raton, United States | NasdaqCM
1.68 USD
-0.10
(-5.618%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 11:34 a.m. EDT
The investment case here is severely compromised by a deteriorating business trajectory. The company has suffered a catastrophic -55% decline over the last six years, with the most recent annual performance showing a brutal -63% drop. This is not a temporary setback; it is a structural collapse in value where the market has priced out the business entirely. Fundamentals confirm the doom: negative earnings, negative free cash flow, and a lack of sales revenue mean there is no organic engine driving the stock higher. While the analyst consensus is aggressively bullish with a $7 target, this ignores the reality that biotech stocks without revenue or cash generation are binary bets on a single future event, not investments in a growing company. The options market reflects this anxiety, with traders buying protection (puts) rather than betting on a rally. There is no dividend to provide a floor, and the balance sheet, while currently liquid, is burning cash. This is a speculative trap disguised by optimistic targets; the long-term outlook is bleak, and the short-term momentum remains firmly in the downside. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.104390 |
| AutoARIMA | 0.124872 |
| AutoETS | 0.129503 |
| MSTL | 0.146756 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 4.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.073 |
| Excess Kurtosis | -0.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 6.9 |
| Market Cap | 46,626,364 |
| Forward P/E | -3.91 |
| Beta | 0.90 |
| Previous Name | INmune Bio, Inc. |
| Website | https://www.inmunebio.com |
As of Oct. 10, 2026, 11:34 a.m. EDT: Speculators are positioning defensively with heavy put volume relative to calls, particularly at the $2.00 strike which sees significant new flow on both sides. Open interest is heavily concentrated out-of-the-money at the $3.00 strike, suggesting a speculative ceiling or a 'glass half full' view of a potential catalyst, while the immediate term is dominated by hedging or short-covering bets against a drop below current levels.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.048128366 |
| Address1 | 225 NE Mizner Blvd. |
| Address2 | Suite 640 |
| All Time High | 30.37 |
| All Time Low | 1.09 |
| Ask | 1.68 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 234,360 |
| Average Daily Volume3 Month | 362,931 |
| Average Volume | 362,931 |
| Average Volume10Days | 234,360 |
| Beta | 0.898 |
| Bid | 1.41 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 0.736 |
| City | Boca Raton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.68 |
| Current Ratio | 4.041 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.79 |
| Day Low | 1.64 |
| Debt To Equity | 6.9 |
| Display Name | INmune Bio |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,048,200 |
| Earnings Call Timestamp Start | 1,786,048,200 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,304,000 |
| Earnings Timestamp Start | 1,793,304,000 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 29,620,366 |
| Eps Current Year | -0.55 |
| Eps Forward | -0.43 |
| Eps Trailing Twelve Months | -0.67 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.1346 |
| Fifty Day Average Change | -0.45459998 |
| Fifty Day Average Change Percent | -0.21296729 |
| Fifty Two Week Change Percent | -4.8128366 |
| Fifty Two Week High | 2.6 |
| Fifty Two Week High Change | -0.91999996 |
| Fifty Two Week High Change Percent | -0.35384616 |
| Fifty Two Week Low | 1.09 |
| Fifty Two Week Low Change | 0.5899999 |
| Fifty Two Week Low Change Percent | 0.5412843 |
| Fifty Two Week Range | 1.09 - 2.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,549,290,600,000 |
| Float Shares | 23,300,138 |
| Forward Eps | -0.43 |
| Forward P E | -3.9069765 |
| Free Cashflow | -10,046,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 21 |
| Fullday Change | -0.100000024 |
| Fullday Change Percent | -5.6179786 |
| Fullday Price | 1.68 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | 0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.107530005 |
| Held Percent Institutions | 0.15595001 |
| Implied Shares Outstanding | 27,753,789 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida. |
| Long Name | INmune Bio Inc. |
| Market | us_market |
| Market Cap | 46,626,364 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_530336663 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-13 |
| Net Income To Common | -18,416,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 55,507,578 |
| Number Of Analyst Opinions | 3 |
| Open | 1.79 |
| Operating Cashflow | -14,961,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Phone | 561 710 0512 |
| Prev Name | INmune Bio, Inc. |
| Previous Close | 1.78 |
| Price Eps Current Year | -3.0545454 |
| Price Hint | 4 |
| Price To Book | 2.2826085 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 3.935 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.100000024 |
| Regular Market Change Percent | -5.6179786 |
| Regular Market Day High | 1.79 |
| Regular Market Day Low | 1.64 |
| Regular Market Day Range | 1.64 - 1.79 |
| Regular Market Open | 1.79 |
| Regular Market Previous Close | 1.78 |
| Regular Market Price | 1.68 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 247,109 |
| Return On Assets | -0.39119998 |
| Return On Equity | -0.74818003 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 27,753,789 |
| Shares Percent Shares Out | 0.0958 |
| Shares Short | 2,657,727 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,183,845 |
| Short Name | INmune Bio Inc. |
| Short Percent Of Float | 0.107200004 |
| Short Ratio | 7.85 |
| Source Interval | 15 |
| State | FL |
| Symbol | INMB |
| Target High Price | 9.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.0 |
| Target Median Price | 8.0 |
| Total Cash | 18,411,000 |
| Total Cash Per Share | 0.663 |
| Total Debt | 1,405,000 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.67 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.63845 |
| Two Hundred Day Average Change | 0.04154992 |
| Two Hundred Day Average Change Percent | 0.025359284 |
| Type Disp | Equity |
| Volume | 247,109 |
| Website | https://www.inmunebio.com |
| Zip | 33,432 |